Simufilam is Cassava's lead drug candidate to treat Alzheimer's disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer's with a simple blood test.
In March 2020, Cassava Sciences initiated a long-term, open-label study to evaluate simufilam in patients with Alzheimer's disease.
The study is funded by a research grant award from the National Institutes of Health.
The Company plans to announce the results of an interim analysis on safety and cognition for the first 50 subjects to complete nine months of open-label drug treatment.
These cognition data will be presented at the 2021 Alzheimer's Association International Conference.
Cassava Sciences will also present biomarker data from the open-label study.
In May 2021, Cassava Sciences initiated a Cognition Maintenance Study (CMS). Patients who previously completed at least one year of open-label treatment with simufilam qualify to enroll in the CMS.
Cassava Sciences plans to initiate a Phase 3 program of simufilam in Alzheimer's disease in the second half of 2021.
The first Phase 3 study is designed to evaluate symptomatic improvement, and the second trial will determine disease-modifying effects of simufilam in Alzheimer's disease.
Price Action: SAVA shares are up 4.60% at $83.31 during the market trading session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.